Close Menu

NEW YORK — Molecular diagnostics firm NuProbe said on Monday that it has closed an oversubscribed $42 million financing round.

The fundraise was led by BioTrack Capital and Yonghua Capital, with participation from Taifu Capital, Panlin Capital, Juming Capital, and Tuobang Capital, as well as existing investors Sequoia Capital China, Ruomu Capital, and Serica Partners.

NuProbe said it will use the proceeds to expand its US and Chinese commercial teams, develop new next-generation sequencing products, and file for Chinese regulatory approval for its clinical products. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The FDA and CDC call for a pause in administering Johnson & Johnson's SARS-CoV-2 vaccine while reports of rare blood clots are looked into, reports the Wall Street Journal.

According to the Associated Press, a Swiss program aims to shepherd long-term science projects and diplomacy.

CNN reports that two new studies suggest the B.1.1.7 SARS-CoV-2 variant may be more transmissible, but may not lead to more severe disease.

In PNAS this week: analysis of pathway affecting acute kidney injury, parental-specific allelic expression in horse placenta, and more.

Apr
16
Sponsored by
Thermo Fisher Scientific

With COVID-19 vaccines rolling out, clinical labs and test developers are preparing for changes in both demand for testing and types of testing for SARS-CoV-2.

Apr
21
Sponsored by
Mission Bio

This webinar, the first in a “Meet the Authors” series sponsored by Mission Bio, will discuss the application of single-cell analysis to decipher clonal evolution across several stages of disease development in myeloid malignancies. 

Apr
22
Sponsored by
10x Genomics

The human immune system is extremely complex, comprised of multiple cell types and states interacting in myriad ways to produce diverse cellular ecosystems.

Apr
29
Sponsored by
Co-Diagnostics

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.